Bispecific anti-VEGF/anti-ANG-2 antibodies
First Claim
Patent Images
1. A bispecific antibody that binds specifically to human vascular endothelial growth factor (VEGF) and human angiopoietin-2 (ANG-2), said antibody comprising a first antigen-binding site that specifically binds to human VEGF and a second antigen-binding site that specifically binds to human ANG-2, wherein:
- i) said antigen-binding sites each comprise an antibody heavy chain variable domain and an antibody light chain variable domain;
ii) said first antigen-binding site comprises in the heavy chain variable domain;
a CDR3 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
1, SEQ ID NO;
9, SEQ ID NO;
17, and SEQ ID NO;
94;
a CDR2 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
2, SEQ ID NO;
10, SEQ ID NO;
18, and SEQ ID NO;
95;
and a CDR1 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
3, SEQ ID NO;
11, SEQ ID NO;
19, and SEQ ID NO;
96, andin the light chain variable domain;
a CDR3 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
4, SEQ ID NO;
12, SEQ ID NO;
20, and SEQ ID NO;
97,a CDR2 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
5, SEQ ID NO;
13, SEQ ID NO;
21, and SEQ ID NO;
98; and
a CDR1 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
6, SEQ ID NO;
14, SEQ ID NO;
22, and SEQ ID NO;
99; and
iii) said second antigen-binding site comprises in the heavy chain variable domain;
a CDR3 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
25, SEQ ID NO;
38, SEQ ID NO;
46, SEQ ID NO;
54, SEQ ID NO;
62, SEQ ID NO;
70, SEQ ID NO;
78, and SEQ ID NO;
86;
a CDR2 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
26, SEQ ID NO;
39, SEQ ID NO;
47, SEQ ID NO;
55, SEQ ID NO;
63, SEQ ID NO;
71, SEQ ID NO;
79, and SEQ ID NO;
87; and
a CDR1 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
27, SEQ ID NO;
40, SEQ ID NO;
48, SEQ ID NO;
56, SEQ ID NO;
64, SEQ ID NO;
72, SEQ ID NO;
80, and SEQ ID NO;
88; and
in the light chain variable domain;
a CDR3 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
28, SEQ ID NO;
28 with the mutations T92L, H93Q and W94T, SEQ ID NO;
41, SEQ ID NO;
49, SEQ ID NO;
57, SEQ ID NO;
65, SEQ ID NO;
73, SEQ ID NO;
81, and SEQ ID NO;
89;
a CDR2 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
29, SEQ ID NO;
42, SEQ ID NO;
50, SEQ ID NO;
58, SEQ ID NO;
66, SEQ ID NO;
74, SEQ ID NO;
82 and SEQ ID NO;
90; and
a CDR1 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
30, SEQ ID NO;
43, SEQ ID NO;
51, SEQ ID NO;
59, SEQ ID NO;
67, SEQ ID NO;
75, SEQ ID NO;
83, and SEQ ID NO;
91.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
65 Citations
18 Claims
-
1. A bispecific antibody that binds specifically to human vascular endothelial growth factor (VEGF) and human angiopoietin-2 (ANG-2), said antibody comprising a first antigen-binding site that specifically binds to human VEGF and a second antigen-binding site that specifically binds to human ANG-2, wherein:
-
i) said antigen-binding sites each comprise an antibody heavy chain variable domain and an antibody light chain variable domain; ii) said first antigen-binding site comprises in the heavy chain variable domain; a CDR3 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
1, SEQ ID NO;
9, SEQ ID NO;
17, and SEQ ID NO;
94;a CDR2 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
2, SEQ ID NO;
10, SEQ ID NO;
18, and SEQ ID NO;
95;and a CDR1 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
3, SEQ ID NO;
11, SEQ ID NO;
19, and SEQ ID NO;
96, andin the light chain variable domain; a CDR3 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
4, SEQ ID NO;
12, SEQ ID NO;
20, and SEQ ID NO;
97,a CDR2 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
5, SEQ ID NO;
13, SEQ ID NO;
21, and SEQ ID NO;
98; anda CDR1 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
6, SEQ ID NO;
14, SEQ ID NO;
22, and SEQ ID NO;
99; andiii) said second antigen-binding site comprises in the heavy chain variable domain; a CDR3 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
25, SEQ ID NO;
38, SEQ ID NO;
46, SEQ ID NO;
54, SEQ ID NO;
62, SEQ ID NO;
70, SEQ ID NO;
78, and SEQ ID NO;
86;a CDR2 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
26, SEQ ID NO;
39, SEQ ID NO;
47, SEQ ID NO;
55, SEQ ID NO;
63, SEQ ID NO;
71, SEQ ID NO;
79, and SEQ ID NO;
87; anda CDR1 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
27, SEQ ID NO;
40, SEQ ID NO;
48, SEQ ID NO;
56, SEQ ID NO;
64, SEQ ID NO;
72, SEQ ID NO;
80, and SEQ ID NO;
88; andin the light chain variable domain; a CDR3 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
28, SEQ ID NO;
28 with the mutations T92L, H93Q and W94T, SEQ ID NO;
41, SEQ ID NO;
49, SEQ ID NO;
57, SEQ ID NO;
65, SEQ ID NO;
73, SEQ ID NO;
81, and SEQ ID NO;
89;a CDR2 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
29, SEQ ID NO;
42, SEQ ID NO;
50, SEQ ID NO;
58, SEQ ID NO;
66, SEQ ID NO;
74, SEQ ID NO;
82 and SEQ ID NO;
90; anda CDR1 region having an amino acid sequence selected from the group consisting of;
SEQ ID NO;
30, SEQ ID NO;
43, SEQ ID NO;
51, SEQ ID NO;
59, SEQ ID NO;
67, SEQ ID NO;
75, SEQ ID NO;
83, and SEQ ID NO;
91. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
Specification